For your patients with overactive bladder (OAB)
MORE TIME HERE LESS TIME THERE WITH GEMTESA1
GEMTESA® is a beta-3 adrenergic agonist indicated for
the treatment of overactive bladder (OAB) with
symptoms of urge urinary incontinence, urgency, and
urinary frequency in adults.
There's more to know about GEMTESA
Where would you like to go?
For more time wherever they want to be, prescribe GEMTESA1
URGENCY IMPROVEMENT
- Proven urgency reduction data in label1
- Statistically significant reduction of all 3 key OAB symptoms* vs placebo at 12 weeks— including urgency1,2†
- ~43% of all OAB patients taking GEMTESA had a 50% reduction in urgency episodes at week 12 vs 38% with placebo3‡
One dose, no titration
- Once-daily 75-mg dose with no titration, to be taken with or without food and swallowed whole with a glass of water1
- Crushability. In adults, GEMTESA tablets may be crushed, mixed with a tablespoon (~15 mL) of applesauce and taken immediately with a glass of water1
NO BLOOD PRESSURE WARNING IN ITS LABEL1
- No association with clinically significant changes to hypertension or increased blood pressure vs placebo1,3§||
*The 3 key symptoms of OAB are urgency, micturition frequency, and urge urinary incontinence (UUI)/leakage.2
†The efficacy of GEMTESA was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.1,3
‡Data were based on unadjusted values for a supportive outcome measure that was a prespecified secondary endpoint in the pivotal EMPOWUR trial.3
§In a 12-week pivotal study, hypertension rates for OAB patients taking GEMTESA (n=545) were 1.7% vs 1.7% with placebo (n=540). Increased blood pressure (BP) rates were 0.7% with GEMTESA vs 0.9% with placebo.3
||In a 4-week, randomized, placebo-controlled, ambulatory BP study in OAB patients (n=200), GEMTESA 75 mg was not associated with clinically significant changes in BP. Mean age 59 years; 75% female. At baseline: 35% of subjects had preexisting hypertension; 29% were taking at least 1 concomitant antihypertensive medication.1
GEMTESA demonstrated statistically significant reduction of all 3 key OAB symptoms* vs placebo at 12 weeks— including urgency1,2†
See the randomized, double-blind study results for each symptom:
*The 3 key symptoms of OAB are urgency, micturition frequency, and UUI/leakage.2
†The efficacy of GEMTESA was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.1
References: 1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609-623. 3. Data on file. Urovant Sciences GmbH.